rates, and swathes of our vulnerable, elderly, and young middle-class population are faced with serious challenges in getting and maintaining medical care because it is inaccessible and unaffordable. Even for patients of comfortable fi nancial means, acquiring health insurance is not an activity for the weak of heart (and that weakness might be interpreted in the future as a preexisting condition).
Who will pay for the exciting innovations I noted above, and who will deliver them? As reimbursement is shrinking, the time demands for physician electronic charting and communications with insurance companies are increasing. More physicians are employed and controlled by healthcare systems. How many will have the time and updated knowledge to discuss the appropriateness and clinical implications of these therapies between the phone calls begging for insurance company approval of coverage and payment?
As corporate taxes appear on the brink of being reduced, we can hope that this corporate fi nancial benefi t will translate to reduced drug and device costs and more affordable insurance for our more vulnerable populations. But this is not certain.
I have concerns as to how clinical science and healthcare delivery can move forward in an environment in which federal directives now prohibit our most respected federal research agencies from using such terms as "vulnerable" (populations) and "evidence-based" to justify their proposals for budgetary support for their ongoing work in population disease health and disease management.
1 Even a short time spent in the hallways or emergency rooms of any of our safety-net hospitals reveals the strain that acute and chronic illness is imposing on the social fabric of families, society, and the often underfunded infrastructure of this aspect of our healthcare system. Who will be in the position to empathetically and objectively assess the value of translating these ongoing efforts in discovery to implementation?
Basic stem cell and genetic research is also under ongoing scrutiny. There remains legitimate fear that ultimate policy decisions will not be made by fully informed scientists and ethicists. The ongoing "dialogue" in the United States around climate change and global warming does not give me confi dence that our current government policy-makers are up to the task of objectively dealing with these more nuanced and emotionally charged issues, particularly while avoiding the expression of any evidence-based rationales.
In 2016, the world lost the iconic musical poet Leonard Cohen. Hopefully, he got it right when he wrote:
Ring the bells that still can ring Forget your perfect offering There is a crack in everything That's how the light gets in -"Anthem"; 1992 I and the rest of our editorial team wish you, our readers, a healthy and peaceful 2018. I am optimistic that we can all fi nd or create at least some light.
